bioMérieux – First-Quarter 2017 Business Review

20 April, 2017

Marcy l'Étoile (France), April 20, 2017 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2017.

Sales

Consolidated sales rose to €568 million for the first three months of 2017, up from €489 million in the same period one year earlier. This represents growth of 16.3% as reported, including a positive currency effect of around €13 million. Organic growth (at constant exchange rates and scope of consolidation) represented 13.7% year-on-year, helped by one extra billing day compared with first-quarter 2016. FilmArray® accounted for around half of the increase, driven by a stronger and longer flu season than in the prior-year period.

  • Strong sales dynamic in first-quarter 2017, with sales up 13.7% at constant exchange rates and scope of consolidation:
  • €568 million in sales
  • Up 16.3% as reported
  • Equipment sales up sharply
  • Accelerated growth in the Asia-Pacific and Europe – Middle East – Africa regions alongside continued fast-paced expansion in the Americas
  • All strategic lines contributed to sales growth, led by a remarkable performance from FilmArray®

Alexandre Mérieux, Chief Executive Officer, said: “Building on our full-year 2016 results, the first-quarter 2017 performance reflects our astute positioning and supports our long-term strategy. In a favorable environment, ongoing momentum in the United States and an acceleration in business in the Asia-Pacific and EMEA regions drove remarkable organic sales growth of 13.7%.”

About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2016, revenues reached €2,103 million, with 90% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market (Symbol: BIM/Reuters: BIOX.PA/Bloomberg: BIM.FP – ISIN: FR0010096479)

Corporate website: www.biomerieux.com
Investor website: www.biomerieux-finance.com

Contacts

Investor Relations

bioMérieux
Sylvain Morgeau
Tel.: +33 (0)4 78 87 22 37
investor.relations@biomerieux.com

Media Relations

bioMérieux
Aurore Sergeant
Tel.: +33 (0)4 78 87 20 53
media@biomerieux.com

Image Sept
Laurence Heilbronn
Tel.: +33 (0)1 53 70 74 64
lheilbronn@image7.fr

Claire Doligez
Tel.: +33 (0)1 53 70 74 48
cdoligez@image7.fr


Download the Full Press Release:

Download
Pioneering diagnostics